Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis

被引：0
|
作者：
Ikeda, Kimiyuki [1 ]
Shiratori, Masanori [1 ]
Yokoo, Keiki [1 ]
Ohtsuka, Mitsuo [1 ]
Chiba, Hirofumi [1 ]
Takahashi, Hiroki [1 ]
机构：
[1] Sapporo Med Univ, Sch Med, Dept Internal Med 3, Sapporo, Hokkaido 0608543, Japan
来源：
EUROPEAN RESPIRATORY JOURNAL | 2013年 / 42卷
关键词：
Interstitial lung disease; Idiopathic pulmonary fibrosis; Treatments;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2600
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
    Glassberg, Marilyn K.
    Wijsenbeek, Marlies S.
    Gilberg, Frank
    Petzinger, Ute
    Kirchgaessler, Klaus-Uwe
    Albera, Carlo
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54 (03)
  • [22] THE PREDICTIVE FACTORS FOR THE EFFECT OF PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS
    Ichimuray
    Tsushima, K.
    Matsumura, T.
    Yokota, A.
    Terada, J.
    Iesato, K.
    Sakao, S.
    Tada, Y.
    Tanabe, N.
    Tatsumi, K.
    RESPIROLOGY, 2014, 19 : 148 - 148
  • [23] Effect Of Pirfenidone On Cough In Patients With Idiopathic Pulmonary Fibrosis
    Van Manen, M. J. G.
    Birring, S. S.
    Vancheri, C.
    Vindigni, V.
    Wapenaar, M.
    Cottin, V.
    Wijsenbeek, M. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [24] Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan
    Ikeda, Kimiyuki
    Chiba, Hirofumi
    Nishikiori, Hirotaka
    Azuma, Arata
    Kondoh, Yasuhiro
    Ogura, Takashi
    Taguchi, Yoshio
    Ebina, Masahito
    Sakaguchi, Hiroki
    Miyazawa, Shogo
    Suga, Moritaka
    Sugiyama, Yukihiko
    Nukiwa, Toshihiro
    Kudoh, Shoji
    Takahashi, Hiroki
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [25] Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan
    Kimiyuki Ikeda
    Hirofumi Chiba
    Hirotaka Nishikiori
    Arata Azuma
    Yasuhiro Kondoh
    Takashi Ogura
    Yoshio Taguchi
    Masahito Ebina
    Hiroki Sakaguchi
    Shogo Miyazawa
    Moritaka Suga
    Yukihiko Sugiyama
    Toshihiro Nukiwa
    Shoji Kudoh
    Hiroki Takahashi
    Respiratory Research, 21
  • [26] Pirfenidone for the treatment of idiopathic pulmonary fibrosis
    Xaubet, Antoni
    Serrano-Mollar, Anna
    Ancochea, Julio
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (02) : 275 - 281
  • [27] The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D
    Takuya Samukawa
    Tsutomu Hamada
    Hirofumi Uto
    Masakazu Yanagi
    Go Tsukuya
    Tsuyoshi Nosaki
    Masahiro Maeda
    Takashi Hirano
    Hirohito Tsubouchi
    Hiromasa Inoue
    BMC Pulmonary Medicine, 12
  • [28] The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D
    Samukawa, Takuya
    Hamada, Tsutomu
    Uto, Hirofumi
    Yanagi, Masakazu
    Tsukuya, Go
    Nosaki, Tsuyoshi
    Maeda, Masahiro
    Hirano, Takashi
    Tsubouchi, Hirohito
    Inoue, Hiromasa
    BMC PULMONARY MEDICINE, 2012, 12
  • [29] Pirfenidone in idiopathic pulmonary fibrosis: Is there a role?
    Galal, I.
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2014, 63 (04): : 749 - 750
  • [30] Pirfenidone treatment of idiopathic pulmonary fibrosis
    Gan, Ye
    Herzog, Erica L.
    Gomer, Richard H.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 : 39 - 47
12345